AI-generated research brief — verify at source
RNA Profiling Identifies Survival Differences and TP53–VEGFA Link in Solid Tumors
In a subset analysis of the IMPACT2 precision oncology trial, patients with altered expression in six or more genes had a notably shorter median overall survival of 6.7 months compared with 11.9 months in those with three to five altered genes, a statistically meaningful difference (p = 0.03). Additionally, TP53 genomic alterations showed significant concordance with VEGFA overexpression at the RNA level, offering a potential mechanistic explanation for bevacizumab sensitivity in TP53-mutant tumors.
What Was Studied
This study examined the degree to which DNA-level genomic alterations correspond to RNA-level expression changes in cancer patients, and whether the number of genes with altered expression carries prognostic significance. Understanding this concordance is essential for evaluating whether RNA profiling adds actionable information beyond standard DNA next-generation sequencing in precision oncology.
How It Was Studied
The analysis drew on patient data from IMPACT2 (NCT02152254), a prospective randomized trial at MD Anderson Cancer Center designed to assess molecular profiling as a guide for treatment selection across multiple tumor types. All 829 enrolled patients underwent DNA next-generation sequencing, while a subset of 253 patients also had RNA profiling performed through Tempus. Survival analyses focused on 217 of those patients who received treatment following RNA profiling. Investigators evaluated concordance between DNA alterations and RNA expression changes at both the individual gene and gene-pair levels, and assessed PD-L1 status alongside the total count of genes with altered expression as potential prognostic variables.
What Was Observed
- Fifty patients showed 58 concordant events in which a genomic alteration and an expression alteration occurred in the same gene; 38 of these events involved copy number changes, and 41 of the 50 patients demonstrated statistically significant concordance. This indicates that, while direct gene-level overlap exists, it is not universal, highlighting that DNA and RNA profiles capture distinct biological information in many cases.
- Across the broader dataset, 123 gene pairs showed statistically significant associations between a genomic alteration in one gene and an expression alteration in another (p < 0.05). One of the most notable associations was between TP53 mutations and overexpression of VEGFA, a finding with potential implications for understanding anti-angiogenic therapy response.
- Median overall survival differed substantially by the number of genes with altered expression: patients with 0–2 altered genes had a median OS of 9.8 months, those with 3–5 had 11.9 months, and those with six or more had only 6.7 months, a statistically significant difference across groups (p = 0.03). The non-linear pattern suggests that a high burden of transcriptomic dysregulation, rather than a simple more-is-worse gradient, may mark a biologically distinct and more aggressive disease state.
Why This Matters
RNA profiling has largely remained investigational in routine oncology practice, with its clinical utility debated relative to the established standard of DNA sequencing. This study provides quantitative evidence that transcriptomic data can yield prognostic stratification independent of genomic profiles and can uncover biologically relevant inter-gene relationships, such as TP53–VEGFA, that are invisible to DNA profiling alone. These findings support the case for integrating RNA profiling into precision oncology frameworks and for designing prospective trials that test RNA-guided therapeutic decisions.
How to Read This Result
Because RNA profiling was available for only 253 of 829 patients and survival analyses were restricted to 217 treated individuals, the cohort is relatively small and potentially subject to selection bias, which limits the generalizability of the prognostic associations reported here.
Limitations
The abstract does not explicitly report study limitations.